A bivalent ligand (KDAN-18) containing δ-antagonist and κ-agonist pharmacophores bridges δ2 and κ1 opioid receptor phenotype

David J. Daniels, Amol Kulkarni, Zhihua Xie, Rashmi G. Bhushan, Philip S Portoghese

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

To characterize δ- and κ-opioid receptor phenotypes, bivalent ligands (KDAN series) containing δ-antagonist (naltrindole) and κ1-agonist (ICI-199,441) pharmacophores were synthesized and evaluated by the intrathecal route using the mouse tail-flick assay and binding studies. The data have suggested that KDAN-18 (2) bridges phenotypic δ2- and K1-receptors. A conceptual model is presented to explain the organizational differences between the opioid receptors that give rise to the phenotypes (δ1, δ2, κ1, κ2).

Original languageEnglish (US)
Pages (from-to)1713-1716
Number of pages4
JournalJournal of Medicinal Chemistry
Volume48
Issue number6
DOIs
StatePublished - Mar 24 2005

Fingerprint

naltrindole
Opioid Receptors
Ligands
Phenotype
Tail
KDAN 18
ICI 199441

Cite this

A bivalent ligand (KDAN-18) containing δ-antagonist and κ-agonist pharmacophores bridges δ2 and κ1 opioid receptor phenotype. / Daniels, David J.; Kulkarni, Amol; Xie, Zhihua; Bhushan, Rashmi G.; Portoghese, Philip S.

In: Journal of Medicinal Chemistry, Vol. 48, No. 6, 24.03.2005, p. 1713-1716.

Research output: Contribution to journalArticle

@article{66293b85b6ee4610b70c38a4dd729180,
title = "A bivalent ligand (KDAN-18) containing δ-antagonist and κ-agonist pharmacophores bridges δ2 and κ1 opioid receptor phenotype",
abstract = "To characterize δ- and κ-opioid receptor phenotypes, bivalent ligands (KDAN series) containing δ-antagonist (naltrindole) and κ1-agonist (ICI-199,441) pharmacophores were synthesized and evaluated by the intrathecal route using the mouse tail-flick assay and binding studies. The data have suggested that KDAN-18 (2) bridges phenotypic δ2- and K1-receptors. A conceptual model is presented to explain the organizational differences between the opioid receptors that give rise to the phenotypes (δ1, δ2, κ1, κ2).",
author = "Daniels, {David J.} and Amol Kulkarni and Zhihua Xie and Bhushan, {Rashmi G.} and Portoghese, {Philip S}",
year = "2005",
month = "3",
day = "24",
doi = "10.1021/jm034234f",
language = "English (US)",
volume = "48",
pages = "1713--1716",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - A bivalent ligand (KDAN-18) containing δ-antagonist and κ-agonist pharmacophores bridges δ2 and κ1 opioid receptor phenotype

AU - Daniels, David J.

AU - Kulkarni, Amol

AU - Xie, Zhihua

AU - Bhushan, Rashmi G.

AU - Portoghese, Philip S

PY - 2005/3/24

Y1 - 2005/3/24

N2 - To characterize δ- and κ-opioid receptor phenotypes, bivalent ligands (KDAN series) containing δ-antagonist (naltrindole) and κ1-agonist (ICI-199,441) pharmacophores were synthesized and evaluated by the intrathecal route using the mouse tail-flick assay and binding studies. The data have suggested that KDAN-18 (2) bridges phenotypic δ2- and K1-receptors. A conceptual model is presented to explain the organizational differences between the opioid receptors that give rise to the phenotypes (δ1, δ2, κ1, κ2).

AB - To characterize δ- and κ-opioid receptor phenotypes, bivalent ligands (KDAN series) containing δ-antagonist (naltrindole) and κ1-agonist (ICI-199,441) pharmacophores were synthesized and evaluated by the intrathecal route using the mouse tail-flick assay and binding studies. The data have suggested that KDAN-18 (2) bridges phenotypic δ2- and K1-receptors. A conceptual model is presented to explain the organizational differences between the opioid receptors that give rise to the phenotypes (δ1, δ2, κ1, κ2).

UR - http://www.scopus.com/inward/record.url?scp=15444364860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444364860&partnerID=8YFLogxK

U2 - 10.1021/jm034234f

DO - 10.1021/jm034234f

M3 - Article

VL - 48

SP - 1713

EP - 1716

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 6

ER -